STOCK TITAN
  1. Home
  2. News
  3. TMCI

Treace Medical Concepts, Inc. - TMCI STOCK NEWS

Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.

Treace Medical Concepts, Inc. is a leading orthopaedic medical device company specializing in innovative solutions for the surgical management of bunion deformities. With a commitment to excellence, the company brings breakthrough technologies to the high-growth $1.1 billion US market for foot and ankle surgical products.

Treace's flagship product, the Lapiplasty® 3D Bunion Correction™ procedure, addresses the root cause of bunions by correcting all planes of the deformity. This patented procedure not only improves patient outcomes but also allows for a quicker return to an active lifestyle.

The company operates as a single segment, focusing on the design, manufacturing, and marketing of medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals. Their mission is to assist foot and ankle physicians in enhancing patient outcomes and reducing healthcare costs, while also providing a rewarding experience for their employees and exceptional returns for shareholders.

In recent news, Treace Medical Concepts announced their participation in the upcoming J.P. Morgan Healthcare Conference, showcasing new SpeedPlate™ configurations, and the full commercial release of the Micro-Lapiplasty™ System. Additionally, they have initiated a limited clinical release of the Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation. The company also focuses on educational outreach to build awareness and reduce stigma around bunion deformities.

Treace Medical Concepts has also partnered to support pickleball players with bunions and related midfoot deformities, helping them to 'get back on their feet' and onto the court. Such initiatives highlight Treace's dedication to improving the lives of individuals affected by foot health issues.

News

Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone

Rhea-AI Summary
Treace Medical Concepts, Inc. sponsors the first National Bunion Day in the U.S. and celebrates treating 100,000 patients with its Lapiplasty® 3D Bunion Correction® System. The company also launches a new patient education campaign.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
News

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance

Rhea-AI Summary
Treace Medical Concepts, Inc. reported strong financial results for Q4 2023 and full-year 2023, with revenue increasing by 25% and 32% respectively. The company's gross margin remained robust at 81.6% in Q4 2023. Treace also saw a significant increase in active surgeons and direct sales representatives. The company's patent portfolio expanded, and it initiated commercialization of new technologies. Despite a net loss, Treace provided optimistic guidance for 2024, expecting revenue growth of 18-20% and improved Adjusted EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.98%
Tags
earnings
-
News

Treace to Report Fourth Quarter and Full-Year 2023 Financial Results

Rhea-AI Summary
Treace Medical Concepts, Inc. will release financial results for the fourth quarter and full year of 2023 after the close of trading on Tuesday, February 27, 2024. The company will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. A live and archived webcast of the event and investor presentation will be available on the Company’s investor relations website. Treace routinely posts important information for investors in the 'Investor Relations' section of its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
conferences earnings
News

Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

Rhea-AI Summary
Treace Medical Concepts, Inc. announces positive three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions. The study demonstrated consistent, positive radiographic and patient-reported outcomes maintained at three years, early return to weight bearing, low radiographic recurrence rates, reduction in pain, and significant improvement in patient-reported quality of life measures. Interim data from the Company’s Mini3D™ prospective, multicenter study also showed favorable clinical and patient-reported outcomes with a mini-incision approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
clinical trial
-
News

Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference

Rhea-AI Summary
Treace Medical Concepts, Inc. announces the full commercial release of its Micro-Lapiplasty™ System and limited clinical release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation. The company will highlight new technology innovations and three-year interim ALIGN3D™ clinical results at the 2024 American College of Foot and Ankle Surgeons Annual Scientific Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
none
-
News

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue

Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific Time. Preliminary unaudited fourth quarter and full-year 2023 revenue results show a significant increase, with revenue of $61.8 million to $62.2 million in the fourth quarter of 2023, an approximate 25% increase at the midpoint over the same period in 2022, and revenue of $186.7 million to $187.1 million for the full-year 2023, an approximate increase of 32% at the midpoint compared to the prior year. Blended average revenue per Lapiplasty® procedure kit sold in the fourth quarter of 2023 was approximately $6,437, a record high and 9% increase over the same period in 2022. The company also saw substantial new active surgeon additions and a 35% increase in direct quota carrying sales representatives over year-end 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
none
News

Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 3:45 pm Pacific Time. The CEO will discuss the company's flagship Lapiplasty® and Adductoplasty® Procedures. The webcast and replay will be available on the investor relations website. Treace routinely posts important information for investors on its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
conferences
-
News

Treace Medical Concepts Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) reported a 23% increase in revenue to $40.8 million for the third quarter of 2023. The company also achieved a 36% year-to-date increase in revenue. The gross margin was 80.4% in the third quarter, and 81.0% year to date. Treace has expanded its patent portfolio to 52 granted U.S. patents, with additional patents worldwide and pending U.S. patent applications. The CEO, John T. Treace, highlighted a 21% increase in the surgeon base and a record blended average selling price of $6,311.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.9%
Tags
earnings
-
News

Treace to Present at Stifel 2023 Healthcare Conference

Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) will participate in a fireside chat at the Stifel 2023 Healthcare Conference on November 14, 2023. The CEO and CFO will discuss the Lapiplasty® 3D Bunion Correction® Procedure. A live webcast and replay will be available on the investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences
News

Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

Rhea-AI Summary
Treace Medical Concepts, Inc. will present new interim data for the ALIGN3D™ clinical study at the AOFAS Annual Meeting. The data shows early return to weight bearing in 8.4 days, low recurrence rate, and 81% reduction in pain. The company also highlights new product innovations, including the SpeedPlate™ and Micro-Lapiplasty™ technologies. Full commercial launch of these technologies is expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
clinical trial

FAQ

What is the current stock price of Treace Medical Concepts (TMCI)?

The current stock price of Treace Medical Concepts (TMCI) is $6.96 as of December 20, 2024.

What is the market cap of Treace Medical Concepts (TMCI)?

The market cap of Treace Medical Concepts (TMCI) is approximately 433.0M.

What does Treace Medical Concepts, Inc. specialize in?

Treace Medical Concepts specializes in innovative solutions for the surgical management of bunion deformities.

What is the Lapiplasty® 3D Bunion Correction™ procedure?

The Lapiplasty® 3D Bunion Correction™ procedure is designed to correct all planes of a bunion deformity, addressing its root cause and allowing for quick patient recovery.

What recent products has Treace Medical Concepts released?

Treace has released the Micro-Lapiplasty™ System, SpeedPlate™ configurations, and introduced the Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation.

How does Treace Medical Concepts support the foot and ankle surgical market?

Treace supports this market by designing, manufacturing, and marketing medical devices that enhance patient outcomes and reduce healthcare costs.

When is Treace Medical Concepts presenting at the J.P. Morgan Healthcare Conference?

Treace Medical Concepts is presenting at the J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 3:45 pm Pacific Time.

What is Treace's focus regarding patient outcomes?

Treace aims to improve patient outcomes by providing innovative surgical solutions that address the root cause of bunion deformities and allow quicker recovery times.

Who are the primary customers of Treace Medical Concepts?

The primary customers include physicians, surgeons, ambulatory surgery centers, and hospitals.

What ethical standards does Treace Medical Concepts adhere to?

Treace prides itself on operating with the highest standards of ethical conduct in all its business operations.

What is the company’s mission?

The mission is to assist foot and ankle physicians in improving patient outcomes and reducing healthcare costs, while providing a rewarding experience for employees and exceptional returns for shareholders.

How is Treace Medical Concepts involved in community outreach?

Treace is actively involved in outreach and education efforts to build awareness, reduce stigma, and correct misconceptions about bunion deformities.

Stock TMCI logo
Treace Medical Concepts, Inc.

Nasdaq:TMCI

TMCI Rankings

#3216 Ranked by Market Cap
N/A Ranked by Dividends

TMCI Stock Data

432.96M
45.77M
24.82%
64.33%
4.79%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
PONTE VEDRA